Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

April 1, 2016April 4, 2016

EMA Grants Orphan Medicinal Status to Eiger’s PAH Treatment Ubenimex

News, Pulmonary Hypertension

The European Medicines Agency (EMA) has granted Orphan Medicinal Product status to Eiger BioPharmaceuticals‘ Bestatin (ubenimex) for the treatment of pulmonary arterial hypertension (PAH). “We are very pleased with the EMA ... Read more

March 31, 2016April 4, 2016

Stanford Children’s Health Pediatric Cardiologist to Be Recognized by American Thoracic Society for Her Work

News, Pulmonary Hypertension

At the American Thoracic Society’s annual meeting in San Francisco in May, Dr. Marlene Rabinovitch of the Lucile Packard Children’s Hospital Stanford will give the J. Burns Amberson Lecture. The lecture recognizes “a career ... Read more

March 30, 2016March 30, 2016

Smokers Who Get Lung Cancer Screenings Should Also Be Encouraged to Quit, Researchers Say

Lung Cancer, News

Experts say smokers who visit a clinician for lung cancer screening should also be encouraged to quit smoking at their appointment, according to a recent article titled “Pairing smoking-cessation services with ... Read more

March 28, 2016March 28, 2016

FDA Approves Teva’s Asthma Drug Cinqair as Add-on Treatment

Asthma, News

Teva Pharmaceutical Industries recently announced the approval of Cinqair (reslizumab) injection by the U.S. Food and Drug Administration (FDA) as an add-on maintenance treatment for patients with severe asthma, age 18 and ... Read more

March 24, 2016March 24, 2016

Actelion’s PAH Therapy, Uptravi (selexipag), Approved for Use in Australia and New Zealand

News, Pulmonary Hypertension

Actelion, Ltd., recently announced the approval of Uptravi (selexipag) by the Therapeutic Goods Administration (TGA) of Australia and the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) for the treatment ... Read more

March 22, 2016March 22, 2016

ProMetic’s Scleroderma Treatment PBI-4050 to Enter Phase 2 Clinical Trial

Idiopathic Pulmonary Fibrosis, News, Scleroderma

ProMetic Life Sciences recently announced the initiation of a Phase 2 clinical trial on PBI-4050 for the treatment of scleroderma, a chronic connective tissue disease for which there is currently ... Read more

March 21, 2016March 21, 2016

Experts Recommend Zephyr EBV as Only Minimally Invasive Emphysema Treatment for Use Outside Clinical Trials

Emphysema, News

Pulmonx, based in Redwood City, California, recently announced the publication of recommendations from a panel of experts offering broad guidance regarding selection of therapies for patients with advanced emphysema. The panel recommended that only ... Read more

March 18, 2016March 18, 2016

Verona Pharma Reports Positive Early Trial Data for its CF, COPD Lead Drug Candidate

Cystic Fibrosis, News

Verona Pharma recently announced positive top-line results from a Phase 2a dose-finding clinical trial using its novel lead drug nebulized formulation of RPL554, a first-in-class inhaled drug under development for ... Read more

March 18, 2016March 18, 2016

Lung and Other Cancers Now Part of Electronic Health Records Accessed by Via Pathways

Lung Cancer, News

Flatiron Health and Via Oncology recently announced that Via Pathways, a tool to streamline workflow and patient care, has added a number of cancers — non-small cell and small-cell lung, rectal mesothelioma, prostate, breast, colon, and multiple ... Read more

March 16, 2016March 16, 2016

Viral Infections May Affect Cystic Fibrosis Patients’ Respiratory Microbiome, Study Says

Cystic Fibrosis, News

Viral infections in patients with cystic fibrosis (CF) have been linked to pulmonary exacerbations, according to the results of a study recently presented at the American Academy of Allergy, Asthma & ... Read more